Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: [Lu]Lu-DOTA-TATE is an effective treatment for metastatic neuroendocrine tumors (NETs) expressing somatostatin receptors. While the tumor uptake [Lu]Lu-DOTA-TATE of has shown potential as a predictive biomarker, patient response to the treatment varies significantly. In this study, we aim to identify a predictive blood-based transcriptomic biomarker to better understand individual responses to [Lu]Lu-DOTA-TATE therapy.
Results: Twenty-six patients were prospectively enrolled in this study. Responders were defined as patients who showed partial response or stable disease and non-responders were defined as patients who showed progressive disease according to RECIST1.1 criteria. Of the 26 patients, responders (n = 20) exhibited distinct gene expression profiles compared to non-responders (n = 6). Among the 21 differentially expressed genes identified between the groups, 13 genes were upregulated in non-responders and were associated with the innate immune system. Weighted Gene Co-expression Network Analysis identified a significant gene module linked to treatment response, with eEF1A1 emerging as a key hub gene correlated with favorable outcomes. Baseline clinical and laboratory parameters did not differ significantly according to treatment response.
Conclusions: This study identifies specific blood transcriptomic profiles associated with the innate immune response and a key hub gene linked to treatment outcomes, suggesting an immune-related component in response to [Lu]Lu-DOTA-TATE therapy. These findings may guide patient selection based on systemic immune markers and inform future therapeutic strategies.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12317932 | PMC |
| http://dx.doi.org/10.1186/s13550-025-01284-w | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A Liquid Biopsy Assay of Exosomal miRNA for Non-invasive Identification of Lymph Node Metastasis in Early Gastric Cancer.
Ann Surg Oncol
September 2025
Department of Surgery, Tokushima University, Tokushima, Japan.
Background: Additional surgical resection is required to achieve curative treatment in patients with early gastric cancer (EGC) due to the potential risk for lymph node metastasis (LNM) after pathological analysis; however, LNM is estimated to occur in approximately 10% of patients with high-risk EGC. In this study, we investigated a blood-based liquid biopsy assay of exosomal microRNA (miRNA) for the non-invasive detection of LNM in patients with high-risk EGC.
Methods: Two genome-wide miRNA expression profiling datasets [GSE164174 and The Cancer Genome Atlas (TCGA)] were analyzed to prioritize biomarkers in pretreatment plasma samples from clinical training and validation cohorts of GC patients.
Accelerated transcriptomic age and susceptibility to traffic-related air pollution among cardiac catheterization patients.
Sci Total Environ
August 2025
Center for Public Health and Environmental Assessment, US EPA, Chapel Hill, NC 27514, United States of America.
Background: Accelerated transcriptomic and/or epigenetic age have been proposed as biomarkers of disrupted systemic health and of increased sensitivity to environmental exposures. Previously, we observed epigenetic age acceleration as a biomarker of sensitivity to air pollution, especially for traffic-related air pollution (TRAP) in urban cohorts.
Methods: Using 1024 participants from the CATHGEN cohort, we evaluated whether increased cardiovascular risk associated with TRAP was modified by transcriptomic aging.
A multivariate cell-based liquid biopsy for lung nodule risk stratification: Analytical validation and early clinical evaluation.
J Liq Biopsy
September 2025
PreCyte, Inc., Seattle, WA, USA.
Background: The Indicator Cell Assay Platform (iCAP) is a novel tool for blood-based diagnostics that uses living cells as biosensors to integrate and amplify weak, multivalent disease signals present in patient serum. In the platform, standardized cells are exposed to small volumes of patient serum, and the resulting transcriptomic response is analyzed using machine learning tools to develop disease classifiers.
Methods: We developed a lung cancer-specific iCAP (LC-iCAP) as a rule-out test for the management of indeterminate pulmonary nodules detected by low-dose CT screening.
SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.
Nat Cancer
August 2025
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Multiple myeloma is a bone marrow (BM) plasma cell malignancy preceded by precursor conditions. BM biopsies are conducted infrequently and can yield inconclusive results due to technical limitations. Profiling circulating tumor cells (CTCs) may enable noninvasive routine clinical assessments but remains challenging.
View Article and Find Full Text PDFBlood-based transcriptomic biomarkers for response to [Lu]Lu-DOTA-TATE therapy in neuroendocrine tumors.
EJNMMI Res
August 2025
Department of Nuclear Medicine, Seoul National University Hospital, 03080, Seoul, Republic of Korea.
Background: [Lu]Lu-DOTA-TATE is an effective treatment for metastatic neuroendocrine tumors (NETs) expressing somatostatin receptors. While the tumor uptake [Lu]Lu-DOTA-TATE of has shown potential as a predictive biomarker, patient response to the treatment varies significantly. In this study, we aim to identify a predictive blood-based transcriptomic biomarker to better understand individual responses to [Lu]Lu-DOTA-TATE therapy.
View Article and Find Full Text PDF